Coronavirus (COVID-19) Collection
Transmission dynamics of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January-February 2022
From the end of 2020, multiple variants of concern have emerged during the COVID-19 pandemic. Most recently, the Omicron variant has become dominant worldwide over other strains, with the potential for the emergence of other new variants or subvariants in the future. The Omicron variants have demonstrated increasing transmissibility and therefore are more challenging to control (Kraemer et al., 2021; World Health Organization, 2022). In general, increased transmissibility for a variant indicates an increased transmission strength, a higher transmission speed, or both.Risk of COVID-19 Transmission Aboard Aircraft: An Epidemiological Analysis Based on the National Health Information Platform
The transmission routes of SARS-CoV-2, the pathogen of COVID-19, remain still partly unclear (Yang and Duan G, 2020). According to present knowledge (Chinese Thoracic Society and Chinese Association of Chest Physicians, 2021), the main transmission routes of COVID-19 are respiratory droplets from close contacts and aerosols in confined spaces (Rabaan et al., 2021; Schijven et al., 2021). However, there is no evidence to exclude the possibility of other routes of transmission, such as gastrointestinal tract transmission (Jiao et al., 2021).Emergence of B.1.1.318 SARS-CoV-2 viral lineage and high incidence of alpha B.1.1.7 variant of concern in the Republic of Gabon
SARS-CoV-2 variants of concern (VOC) appear to spread more easily. Other emerging variants are also gaining attention, either known as a "variants of interest" (VOI) or "variants under investigation" (VUI), which increase transmission, warranting further studies. Since the onset of the COVID-19 pandemic, the SARS-CoV-2 genomes have accumulated genetic diversity, leading to increased transmission with altered viral properties (Kraemer et al. 2021).Epidemiological and clinical features of SARS-CoV-2 cluster infection in Anhui Province, Eastern China
COVID-19, a new contagious respiratory disease, occurred at the end of 2019, in Wuhan, China (Zu et al., 2020), and spread globally rapidly. Although various endeavors have been taken, the disease has not been well controlled except in a few countries. Up to now, COVID-19 has led to over millions of deaths, and become a pandemic and global public health crisis. The pathogen of COVID-19 was quickly confirmed to be SARS-CoV-2 (Schijns et al., 2020).Third wave of COVID-19 in Madrid, Spain
Madrid has been the epicenter of COVID-19 in Spain, primarily due to its high population density and mobility. The city has 3.3 million people, with 6.8 million across the metropolitan area. Up to March 15 2021, roughly 605 000 persons had been diagnosed with SARS-CoV-2 infection and 14 000 had died in the Madrid region (Ministerio de Sanidad, 2021; Instituto Nacional de Estadística, 2021). These figures refer to laboratory-confirmed cases, which underestimate the true number as testing access was limited during the earlier stages of the pandemic (Soriano and Barreiro, 2020).Impact of the COVID-19 pandemic on tuberculosis management in Spain
On 31 December 2020, China first reported a group of cases with atypical pneumonia caused by the SARS-CoV-2 (Lu et al., 2020). As of 8 December 2020, more than 68.5 million people were infected with the virus, and >1.5 million have died as a result of it (World Health Organization, 2020). In Spain, to date, >1.5 million people have been diagnosed with COVID-19 infection, and 47 624 people have died from the disease (Spanish Government, 2020). To reduce the risk of transmission, governments have launched urgent measures that include widespread use of facemasks, closure of public spaces and personal mobility restrictions.The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19
SARS-CoV-2, the virus causing Coronavirus disease 2019 (COVID-19), has infected more than 92 million people and lead to the death of more than 1.9 million people worldwide since its outbreak in December 2019 (WHO, 2020). The disease has a wide range of presentations, from asymptomatic infection to fever, cough, shortness of breath and the loss of taste and smell. Symptoms normally appear 2–14 days following exposure to the virus and may develop into mild upper respiratory tract infections or progress to severe pneumonia, which can progress to acute respiratory distress, shock, multiorgan failure and death (Huang et al., 2020; Wang et al., 2020).Surveillance of common respiratory infections during the COVID-19 pandemic demonstrates the preventive efficacy of non-pharmaceutical interventions
The outbreak of novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced disease, COVID-19, spread rapidly from Wuhan, China, in December 2019. This led to China experiencing a major public health emergency with over 83,000 confirmed cases and 4634 deaths as of June 2020 (Rai et al., 2020). Although there are a few newly developed vaccines and treatments, it is conceivable that without some impact on transmission, the virus will continue to circulate, infect, and cause serious disease, in certain segments of the unvaccinated population.Parallel trends in the transmission of SARS-CoV-2 and retail/recreation and public transport mobility during non-lockdown periods
The mobility of hosts and/or vectors has always influenced the transmission of disease (Tizzoni et al., 2014), and this is true for coronavirus disease 2019 (COVID-19) (Kraemer et al., 2020).
